S-1: Klotho Neurosciences Registers 35M Shares for Resale

Klotho Neurosciences, Inc. filed an S-1 registration statement for the resale of up to 35 million shares of common stock by existing selling stockholders, including shares convertible from Series C Preferred Stock.

Summary

• Klotho Neurosciences, Inc. has filed an S-1 registration statement for the resale of up to 35,000,000 shares of common stock by identified selling stockholders.
• Of the shares being registered, 34,000,000 are issuable upon the conversion of Series C Convertible Preferred Stock, and 1,000,000 shares are already held by an existing selling stockholder.
• The company will not receive any proceeds from the resale of these shares by the selling stockholders.
• The Series C Convertible Preferred Stock was sold in a private placement for an aggregate purchase price of $15,000,000, involving 3,400 shares at a price of $4,400 per share.
• The Series C Preferred Stock is convertible into common stock at an effective price of $0.44 per share, with a conversion ratio of 10,000 common shares per Series C Preferred share.
• The closing of the private placement for the Series C Preferred Stock is expected to occur on or before December 31, 2025.
• The company's common stock is traded on the NASDAQ Capital Market under the symbol KLTO, with an average high and low sales price of $0.43 per share on December 2, 2025.
• Investment in the common shares involves a high degree of risk, and investors should be prepared for a complete loss.
• Beneficial ownership limitations apply to Series C Preferred Stock conversions, restricting any single holder to 9.999% and all Series C holders collectively to 19.99% of outstanding common stock until stockholder approval.
• The company has never declared or paid cash dividends on its common stock and does not anticipate doing so in the foreseeable future, intending to retain earnings for business use.
• Estimated expenses for effecting the registration of these shares, borne by the company, total $31,000, including SEC registration fees, accountant fees, legal fees, and miscellaneous costs.

Sentiment

Score: 5

Explanation: The filing is a procedural registration for the resale of shares following a private placement, which is a neutral event. While it provides liquidity for investors, it does not directly raise new capital for the company and highlights significant dilution potential and investment risks. The successful private placement is a positive, but the lack of new capital from this specific filing and the inherent risks balance the sentiment.

Positives

• The company successfully completed a private placement of Series C Preferred Stock, raising $15,000,000, which strengthens its capital base.
• The registration of shares for resale provides liquidity for existing investors, which can make future private capital raises more attractive.
• The company's common stock is listed on the NASDAQ Capital Market, providing access to public markets for trading.

Negatives

• The company will not receive any proceeds from the resale of the 35,000,000 common shares, meaning no direct capital infusion from this specific offering.
• The offering involves a high degree of risk, and investors are cautioned that they could lose their entire investment.
• The potential conversion of 34,000,000 Series C Preferred shares into common stock represents significant potential dilution for existing common stockholders.
• The company has a stated policy of not paying cash dividends in the foreseeable future, which may not appeal to income-focused investors.
• Beneficial ownership limitations and the requirement for stockholder approval for certain conversions could add complexity to the capital structure and future financing flexibility.

Risks

• An investment in the company's securities involves a high degree of risk, and investors should only purchase shares if they can afford a complete loss.
• The market or trading price of the common stock could decline due to various risks, including those detailed in the company's Annual and Quarterly Reports.
• Sales of significant amounts of common shares by selling stockholders could adversely affect the prevailing market price of the common shares and impair the company's ability to raise capital through additional equity issuances.
• Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated.
• Indemnification for liabilities arising under the Securities Act may be against public policy and therefore unenforceable.
• The company may become involved in various lawsuits and legal proceedings in the ordinary course of business, and an adverse result could materially affect its business, financial condition, or operating results.

Future Outlook

The closing of the private placement for the Series C Preferred Stock is expected to occur on or before December 31, 2025. The company does not anticipate paying any cash dividends on its common stock in the foreseeable future, planning instead to retain any earnings for use in its business. Management believes that the assumptions and expectations reflected in forward-looking statements are reasonable, but acknowledges that actual results may differ materially due to various risks and uncertainties.

Management Comments

• Management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, but there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual results will not be different from expectations expressed in this report.
• We do not anticipate paying any cash dividends on our common stock in the foreseeable future. Instead, we will retain any earnings for use in our business.

Industry Context

As a neuroscience company, Klotho Neurosciences operates in a capital-intensive biotechnology sector where significant funding is often required for research, development, and clinical trials. This S-1 filing, primarily for the resale of shares following a private placement, is a common mechanism in the biotech industry to provide liquidity to early-stage investors. While it doesn't directly raise new capital for the company, it facilitates investor exits, which can be crucial for attracting future private funding rounds. The high-risk nature of investing in such companies, as highlighted in the filing, is typical for the sector, given the uncertainties inherent in drug development and regulatory approvals.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not aware of any legal proceedings or claims that will have, individually or in the aggregate, a material adverse effect on its business, financial condition, or operating results.
• The company may become involved in various lawsuits and legal proceedings that may arise in the ordinary course of business, which are subject to inherent uncertainties and could have an adverse effect.

Related Party Transactions

• Employment Agreement with Jeffrey LeBlanc (CFO) on August 15, 2024, for an annual base salary of $325,000, an initial equity award of 100,000 common shares, and an additional equity award of 400,000 common shares vesting over two years.
• Employment Agreement with Dr. Joseph Sinkule (CEO) on October 24, 2024, for an annual base salary of $360,000 and an equity award of 1,000,000 options.
• Sigma9 Capital, Ltd. and Aldersgate Capital Partners Ltd., both selling stockholders, share Jason Butcher as manager, who has sole voting control and investment discretion over their beneficially owned securities. Their business address is c/o of the Company.

Stakeholder Impact

• **Shareholders**: Face potential dilution from the conversion of Series C Preferred Stock into common shares. The registration provides liquidity for selling stockholders, which could lead to selling pressure on the stock. The investment is noted as high risk with potential for complete loss.
• **Investors in Series C Preferred Stock**: Will gain the ability to convert their preferred shares into common stock and resell them on the open market, providing an exit strategy for their private investment.
• **Management**: Key executives (CEO and CFO) have employment agreements with competitive salaries and equity awards, aligning their interests with long-term company performance.
• **Creditors**: The $15 million capital raise from the Series C Preferred Stock private placement strengthens the company's financial position, potentially improving its creditworthiness, though the proceeds from this specific resale do not go to the company.

Next Steps

• The registration statement must become effective before the selling stockholders can commence selling the registered securities.
• The closing of the private placement for the Series C Convertible Preferred Shares is expected to occur on or before December 31, 2025.
• Selling stockholders may offer and resell their shares from time to time through various methods on the NASDAQ Capital Market or in private transactions.
• The company will reserve and keep available sufficient authorized common stock for the purpose of issuance upon the conversion of all outstanding Series C Preferred Stock.
• Stockholder approval may be required for conversions of Series C Preferred Stock that would result in aggregate common stock ownership exceeding 19.99% of the company's outstanding common stock.

Key Dates

Recommendation

This S-1 filing is primarily a procedural step to register shares for resale by existing investors following a private placement. While it provides liquidity for those investors, it does not inject new capital into the company. The potential for significant dilution from the conversion of Series C Preferred Stock, coupled with the stated high degree of investment risk and no anticipated dividends, suggests a 'hold' recommendation. Investors should monitor the actual sales by selling stockholders and the company's operational progress, particularly in its neuroscience pipeline, before considering further investment.

Keywords

Klotho Neurosciences, S-1, Registration Statement, Common Stock, Series C Preferred Stock, Resale, Private Placement, NASDAQ, Biotechnology, Neurosciences, Equity Offering, Investment Risk